NIFTY 50 Close 29 Oct

Q1 FY27 earnings results

Apr–Jun 2026 quarter · revenue and profit against the same quarter last year (YoY) and the quarter before (QoQ). INR crore, consolidated where filed.

387 companies have reported Apr–Jun 2026 and 936 more have a results date ahead. 78% grew profit from a year ago; the typical company's sales grew +18.6% and profit +27.0%. Strongest sector: Chemicals (+53.7%); weakest: Oil Gas & Consumable Fuels (-17.9%).

Declared
387/ 1323
29% of scheduled reporters
Profit breadth
78%/22%
grew / declined · 343 comparable
Median sales growth
+18.6%
year on year, all reporters
Median profit growth
+27.0%
year on year, all reporters
Operating margin
236/142
expanded / shrank vs a year ago
Strongest / weakest

Chemicals +53.7%

Oil Gas & Consumable Fuels -17.9%

median profit growth, 5+ reporters
1–9 of 9
CompanyRevenue (₹ Cr)Net profit (₹ Cr)Per shareQuarter
SymbolSectorReportedYoYQoQReportedYoYQoQEPS (₹)Verdict8Q profit
DRREDDYDr. Reddy's Laboratories LimitedHealthcare8,100-5.5%+7.3%436-69.1%+97.3%5.32ShrinkingQ3 FY25 1,404 · Q4 FY25 1,587 · Q1 FY26 1,410 · Q2 FY26 1,337 · Q3 FY26 1,190 · Q4 FY26 221 · Q1 FY27 436
CIPLACipla LimitedHealthcare7,119+2.3%+8.8%786-39.2%+44.8%9.77MixedQ3 FY25 1,575 · Q4 FY25 1,214 · Q1 FY26 1,292 · Q2 FY26 1,353 · Q3 FY26 674 · Q4 FY26 543 · Q1 FY27 786
TORNTPHARMTorrent Pharmaceuticals LimitedHealthcare4,921+54.8%+17.3%566+3.3%+55.5%16.72GrowingQ3 FY25 503 · Q4 FY25 498 · Q1 FY26 548 · Q2 FY26 591 · Q3 FY26 635 · Q4 FY26 364 · Q1 FY27 566
MANKINDMankind Pharma LimitedHealthcare4,031+12.9%+17.1%574+29.0%+2.7%13.75GrowingQ3 FY25 385 · Q4 FY25 425 · Q1 FY26 445 · Q2 FY26 520 · Q3 FY26 414 · Q4 FY26 559 · Q1 FY27 574
ERISEris Lifesciences LimitedHealthcare873+12.9%+15.3%143+14.4%-48.7%10.28GrowingQ3 FY25 87 · Q4 FY25 102 · Q1 FY26 125 · Q2 FY26 134 · Q3 FY26 109 · Q4 FY26 279 · Q1 FY27 143
SYNGENESyngene International LimitedHealthcare736-15.8%-29.0%-9-110.3%-106.1%-0.22LossQ3 FY25 131 · Q4 FY25 183 · Q1 FY26 87 · Q2 FY26 67 · Q3 FY26 15 · Q4 FY26 148 · Q1 FY27 -9
ONESOURCEOnesource Specialty Pharma LimitedHealthcare449+37.3%+4.9%25n/a+400.0%2.18Back to profitQ3 FY25 -69 · Q4 FY25 98 · Q1 FY26 0 · Q2 FY26 10 · Q3 FY26 -89 · Q4 FY26 5 · Q1 FY27 25
ACUTAASAcutaas Chemicals LimitedHealthcare330+59.4%-23.8%75+70.5%-44.0%9.07GrowingQ3 FY25 45 · Q4 FY25 63 · Q1 FY26 44 · Q2 FY26 72 · Q3 FY26 106 · Q4 FY26 134 · Q1 FY27 75
CONCORDBIOConcord Biotech LimitedHealthcare261+27.9%-19.9%61+41.9%-32.2%5.85GrowingQ3 FY25 74 · Q4 FY25 142 · Q1 FY26 43 · Q2 FY26 63 · Q3 FY26 68 · Q4 FY26 90 · Q1 FY27 61

Verdict: Growing sales and profit both up on a year ago · Shrinking both down · Mixed one up, one down · Back to profit a profit after a loss a year ago · Loss a loss this quarter. "n/a" means a year-ago or previous figure isn't available, or it was a loss, so a percentage would mislead.